日前，漳州市九龙江闽台润信石化产业基金公开遴选第一批子基金管理机构：为深入贯彻福建省漳 州市《千百亿产业培育行动加护》决策部署，按照市属国企设立基金支持漳州市产业集群工作方 案, 漳州市九龙江闽台润信石化产业基金（以下简称"九龙江母基金"）拟联合社会资本组建设立子 基金，现公开遴选基金管理机构，有关事项公告如下： 公告指出：九龙江母基金立足福建漳州，放眼全国，主要投向漳州市"9+5"产业集群产业领域及 国家战略新兴产业领域项目，重点支持福建省"专精特新"企业，关注漳州市产业招引集聚。具体 行业上，九龙江母基金重点关注新一代信息技术、智能制造、绿色石化与新材料、医疗健康先进产 业群，新一代信息技术重点关注集成电路半导体、数字经济、人工智能领域(包括软件和硬件);智 能制造重点布局新能源汽车及零部件、机器人与数控机床、航空航天领域、新能源及装备领域;绿 色石化与新材料重点关注高端新材料、关键基础性及战略性材料、精细化工领域；医疗健康先关注 医疗器械、生物医药、生物制造及中医药领域等。 据悉，科创子基金定位为九龙江母基金出资设立。科创子基金主要投向新一代信息技术、智能制 造、绿色石化与新材料、医疗健康先进产业群及国 ...

Core Viewpoint - Guangzhou Deep Medical Instrument Technology Co., Ltd. has completed its Series A financing, indicating strong interest from medical investment funds in the field of microscope surgical robots and recognition of the company's unique technology and execution capabilities [1][3]. Group 1: Company Overview - Deep Medical is a founding member of the Microsurgery Branch of the China Medical Device Industry Association, focusing on intelligent devices for all aspects of microscope surgery [3][17]. - The flagship product, FUNZAR microscope surgical robot, has been recognized as a significant advancement in microsurgery for two consecutive years (2024/2025) and was ranked first among the top five advancements in 2025 [3][17]. Group 2: Technological Innovation - FUNZAR is the world's first modular universal microscope surgical robot system, aiming to redefine the standards of microscope surgery with its innovative design [8][9]. - The system features hand-eye integration with a magnification capability of 10-100 times, allowing surgeons to operate with precision [8]. - FUNZAR employs a modular design with multiple robotic arms, enabling autonomous operations without the need for assistant surgeons [9][10]. Group 3: Clinical Progress - Since its official operation in April 2024, Deep Medical has rapidly progressed through product development, animal testing, and clinical trials, achieving the first clinical enrollment in December 2024 [12]. - Clinical trials for FUNZAR are currently underway in top hospitals across Beijing, Shanghai, Changsha, and Guangzhou, demonstrating its technical advantages and stability [12]. Group 4: Investment and Support - The company has received continuous support from investors like Wanfu Chuanggu and Kangjun Capital, who recognize the strategic value of universal microscope surgical robots [13][14]. - Kangjun Capital emphasizes the innovative technology and execution capabilities of the team, highlighting the potential for FUNZAR to address clinical challenges in microsurgery [14][16].

Group 1 - The company N Beixin-U (688712) was listed today, opening with a rise of 187.16%, and closing with a gain of 183.33%, with a total trading volume of 28.16 million shares and a turnover of 1.409 billion yuan, resulting in a turnover rate of 75.88% [1][2] - The company specializes in the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to provide transformative solutions for cardiovascular disease diagnosis and treatment [1] - The core products include the intravascular ultrasound (IVUS) diagnostic system, which is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, and the fractional flow reserve (FFR) measurement system, which is the first domestically approved product in the gold standard FFR field [1] Group 2 - The total number of shares issued by the company is 57 million, with an online issuance of 13.68 million shares at a price of 17.52 yuan per share, resulting in a final online subscription rate of 0.03264275% [2] - The initial fundraising amount is 999 million yuan, primarily directed towards the construction of an industrial base for interventional medical devices, research and development projects, working capital supplementation, and marketing network construction [2]

证券日报网讯2月5日，科华生物（002022）在互动平台回答投资者提问时表示，面对行业政策与市场环 境的双重挑战，公司将坚守"全而精""融合创新"战略定位，以国民健康需求为核心导向，多措并举推动 企业稳健发展：(1)强化研销协同，挖掘增长新动能。公司持续保持研发投入，研发端聚焦多方法学技 术突破，构建覆盖全场景的整体解决方案，不断增强公司核心竞争力；营销端持续完善国内外销售与服 务网络，加速拓展海外市场，提升产品国际市场渗透率，培育新的业绩增长曲线。(2)深化精益管理， 推进数智化升级。公司将持续推进全价值链降本增效，通过精益管理优化资源配置效率，推动经营管理 数智化转型，充分释放提质增效潜力，提升整体运营效能，筑牢高质量发展根基。 ...

Group 1 - The core viewpoint of the articles highlights the significant progress and opportunities arising from the opening-up policies in Hainan, particularly in the medical and service sectors [1][2][3] - KaiLi Biomedical Technology (Haikou) Co., Ltd. has successfully exported medical electronic endoscope components, benefiting from the "two ends outside" bonded maintenance policy, which has reduced overall costs by 20% to 30% [1] - Hainan's government is focusing on enhancing its openness, with specific tasks such as expanding the range of "zero tariff" goods and reducing the negative list for cross-border service trade [1][2] Group 2 - The opening-up policies have led to a significant increase in economic activity, with over 10,000 new beneficiaries of the "zero tariff" policy and an increase of 26,800 new business entities [2] - Hainan aims to align its policies with international high-standard trade rules, particularly in areas like data cross-border flow and digital copyright protection [3] - The province is prioritizing cooperation with ASEAN, aiming to enhance trade and collaboration in sectors such as cross-border e-commerce and agriculture [3]

Core Viewpoint - Longshen Rongfa has obtained a medical device production license from the Gansu Provincial Drug Administration, allowing its blood dialysis concentrate (powder) product to be produced and sold [1] Group 1: Company Developments - The acquisition of the medical device production license signifies that the company's blood dialysis concentrate (powder) product is now qualified for production and market sales [1] - The blood dialysis concentrate (powder) is utilized in the treatment of acute and chronic renal failure through blood dialysis, and it has been widely applied in clinical settings [1]

Core Viewpoint - The company, Longshen Rongfa (300534), has obtained a Medical Device Manufacturing License from the Gansu Provincial Drug Administration, allowing its blood dialysis concentrate (dry powder) product to be produced and sold [1] Group 1 - The acquisition of the Medical Device Manufacturing License signifies that the company's blood dialysis concentrate (dry powder) product is now qualified for production and market sales [1] - The blood dialysis concentrate (dry powder) is classified as a medical device used in the treatment of acute and chronic renal failure through blood dialysis, and it has been widely applied in clinical settings [1]

Core Viewpoint - The company has obtained a medical device production license for its blood dialysis concentrate (dry powder) product, enabling production and market sales [1] Group 1 - The license was issued by the Gansu Provincial Drug Administration on February 5, 2026 [1] - The blood dialysis concentrate (dry powder) is used for blood dialysis treatment in acute and chronic renal failure and has been widely applied in clinical settings [1]

Core Viewpoint - The company, Longshen Rongfa, has obtained a Medical Device Manufacturing License from the Gansu Provincial Drug Administration, allowing it to produce and sell its blood dialysis concentrate (powder) products, which are essential for treating acute and chronic renal failure [1] Group 1 - The acquisition of the Medical Device Manufacturing License signifies that the company's blood dialysis concentrate (powder) products are now qualified for production and market sales [1] - Blood dialysis concentrate (powder) is widely used in clinical settings for blood dialysis treatment in patients with acute and chronic renal failure [1] - This license acquisition will facilitate the company's production and operational efforts for the blood dialysis concentrate (powder) products, enhancing its industry layout and fostering new profit growth points [1] Group 2 - The development is expected to improve the company's overall market competitiveness and has positive implications for its future growth [1]

Group 1 - The company, Longshen Rongfa, announced that it obtained a medical device production license from the Gansu Provincial Drug Administration on February 5, 2026 [1] - The production scope of the license includes Class III medical devices specifically for blood purification and peritoneal dialysis equipment [1]